Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases.
Adenoma
/ genetics
Adult
Aged
Aged, 80 and over
CD8-Positive T-Lymphocytes
/ immunology
Colorectal Neoplasms
/ genetics
DNA Copy Number Variations
/ genetics
Female
Genetic Drift
Genome, Human
/ genetics
Hepatitis A Virus Cellular Receptor 2
/ genetics
Humans
Immunity
/ genetics
Male
Middle Aged
Neoplasm Recurrence, Local
/ genetics
Postoperative Period
Programmed Cell Death 1 Receptor
/ genetics
Progression-Free Survival
Receptors, Antigen, T-Cell
/ genetics
Journal
PLoS genetics
ISSN: 1553-7404
Titre abrégé: PLoS Genet
Pays: United States
ID NLM: 101239074
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
10
10
2019
accepted:
11
09
2020
revised:
05
02
2021
pubmed:
22
1
2021
medline:
23
4
2021
entrez:
21
1
2021
Statut:
epublish
Résumé
A Darwinian evolutionary shift occurs early in the neutral evolution of advanced colorectal carcinoma (CRC), and copy number aberrations (CNA) are essential in the transition from adenoma to carcinoma. In light of this primary evolution, we investigated the evolutionary principles of the genome that foster postoperative recurrence of CRC. CNA and neoantigens (NAG) were compared between early primary tumors with recurrence (CRCR) and early primary tumors without recurrence (precancerous and early; PCRC). We compared CNA, single nucleotide variance (SNV), RNA sequences, and T-cell receptor (TCR) repertoire between 9 primary and 10 metastatic sites from 10 CRCR cases. We found that NAG in primary sites were fewer in CRCR than in PCRC, while the arm level CNA were significantly higher in primary sites in CRCR than in PCRC. Further, a comparison of genomic aberrations of primary and metastatic conditions revealed no significant differences in CNA. The driver mutations in recurrence were the trunk of the evolutionary phylogenic tree from primary sites to recurrence sites. Notably, PD-1 and TIM3, T cell exhaustion-related molecules of the tumor immune response, were abundantly expressed in metastatic sites compared to primary sites along with the increased number of CD8 expressing cells. The postoperative recurrence-free survival period was only significantly associated with the NAG levels and TCR repertoire diversity in metastatic sites. Therefore, CNA with diminished NAG and diverse TCR repertoire in pre-metastatic sites may determine postoperative recurrence of CRC.
Identifiants
pubmed: 33476333
doi: 10.1371/journal.pgen.1009113
pii: PGENETICS-D-19-01707
pmc: PMC7864431
doi:
Substances chimiques
HAVCR2 protein, human
0
Hepatitis A Virus Cellular Receptor 2
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1009113Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Nat Commun. 2018 Jul 23;9(1):2884
pubmed: 30038269
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
PLoS Comput Biol. 2015 Nov 25;11(11):e1004503
pubmed: 26606115
Protein Sci. 2014 Mar;23(3):260-72
pubmed: 24375592
Nucleic Acids Res. 2013 Apr;41(7):e89
pubmed: 23471004
Nat Genet. 2015 Mar;47(3):209-16
pubmed: 25665006
Cell. 2017 Nov 30;171(6):1259-1271.e11
pubmed: 29107330
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
Cancer Cell. 2018 Apr 9;33(4):676-689.e3
pubmed: 29622463
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16910-5
pubmed: 20837533
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Clin Cancer Res. 2020 Apr 15;26(8):1997-2010
pubmed: 31964786
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
PLoS Genet. 2016 Feb 18;12(2):e1005778
pubmed: 26890883
Genome Biol. 2013;14(10):R120
pubmed: 24172663
Nature. 2018 Jan 25;553(7689):467-472
pubmed: 29342134
Oncoimmunology. 2015 Jan 7;3(12):e968467
pubmed: 25964866
Front Immunol. 2013 Dec 23;4:456
pubmed: 24391640
J Immunol. 2011 May 1;186(9):5173-83
pubmed: 21441454
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Nature. 2019 Jan;565(7739):312-317
pubmed: 30602793
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Cell Rep. 2014 Feb 13;6(3):514-27
pubmed: 24462293
Nature. 2010 Oct 28;467(7319):1114-7
pubmed: 20981102
Nat Genet. 2014 Mar;46(3):225-233
pubmed: 24487277
Science. 2014 Jan 10;343(6167):189-193
pubmed: 24336570
Nat Methods. 2014 Jun;11(6):653-5
pubmed: 24793455